PODD - Earnings call transcript Q2 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen and welcome to the Insulet Corporation Second Quarter 2021 Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, Deborah Gordon, Vice President and Investor Relations.

Deborah Gordon

Thank you, Dalam. Good afternoon and thank you for joining us for Insulet’s second quarter 2021 earnings call. Shacey Executive and Financial Vice are and Executive Officer. today McMillan, Wayde President me Petrovic, Chief President Officer With and Chief discussing website. will be Both the on the results this of section available full our of Relations release our and guidance the XXXX second XXXX call year Investor quarter replay press and

to and made during this refer call Before we to cautionary like expectations. Insulet would the differ inform you current be limitations our by for forward-looking could such in begin, I that materially from certain of statements. SEC statements detailed a statements may of the Please filings inherent explanation

We and effect period exchange. These will to EBITDA constant respect currency with as measures align measures uses revenue, are that of interested foreign to with revenue management non-GAAP also the operating our financial what measures which our measures excluding assessing adjusted of we our operating period. performance, parties namely supplemental performance is and believe and discuss growth from investors, to other as analysts helpful in performance

percentage otherwise and commentary Shacey. which exception call revenue be basis. currency rates, stated, financial year-over-year be to With reported a will with constant regarding on all turn of growth a dollar I that, the will will unless basis over on Additionally, year-over-year changes the

Shacey Petrovic

Deb. Good joining for you, Thank afternoon everyone you and us. thank

business. our underlying on of year momentum and to focus our solid deliver strategy growth fundamentals operational are maintained the and continue midpoint have and driving have of the the sustained our We reached financial and strong. across executing performance and sharp business We’ve

including acceleration of on track double-digit during we the is outlook revenue deliver to are half. Our another strong second and year meaningful growth, also

we growth, Omnipod achieved quarter, of including second XX%. total revenue the During growth XX%

volume U.S. met our of these, channel. both Absent expectations. that pharmacy drove the rebate headwind results in in revenue higher-than-anticipated and terms exceeded expectations our growth mix results we Our adjustments benefit from a despite

new Omnipod future. gives great and quarterly of us for another We also customer record confidence starts, and U.S. global achieved Insulet’s enthusiasm which

MDI efforts, While market our are imperatives. terrific team positioned, growth X remains conversions across at and progress squarely the X continued the We and clearance Type having of unlocking we the pharmacy, data Type Type we’re of once strategic accomplishments presented and conferences. of demonstrate and with again ATTD compelling Omnipod launch the focused expect each market product These innovative clinical with the X. in Omnipod the in coverage where the success ADA X adoption Omnipod volume we business expanded uniquely drove acceleration our strong model, we the and made X both DASH market in drove on our

of system delivered advantages in Omnipod, performance power to the consistently critical the unique automated business market, customer an we model and speaks areas pay-as-you-go in We the differentiated strong insulin of without have these the delivery experience which our provide.

X review workload. are given we the Omnipod the final system, are diligence particularly in the our AID Regarding the of appreciative process of and agency’s collaboration, pandemic incredibly and stages FDA

diabetes that of now remain XXXX, excited happen and continue believe about incredibly clearance Omnipod release the in and offer we FDA unlikely to limited second half We what While we quarter. both will market in QX clearance fourth estimate expect X is the later the will community.

introduction will Our the of Omnipod which greatly by market position, already strong, is X. enhanced be

made our support. securing in teams, sales great capacity payer our well are We prepared, and progress expanded manufacturing have invested

areas of the these we will in clearance stages work the efforts Our process. as through continue final

global more diabetes expanding innovation, our access and addressable strategic X, excellence. delivering imperatives, will the Omnipod each in successful operational market launch global and We I growing a to with now more awareness, speak that market a and on access Beginning share minutes. consumer-focused I it with are too growing in driving remains including CGM few of of confident market, technology Type and and X will be our awareness, and fast of critically of among diabetes people underserved, of living a low. people remain to growing and awareness to and Despite large millions diagnosed with Type is year access X and this rapidly, adoption rapid recently, newly expected diabetes. alone such far

new sizable a new globe of QX. XX% our our access We percentage increase In new U.S. X DASH DASH sequential strong second continue through In numbers more U.S. years. to volume the our drive this the physicians the users provides of grew increase. Omnipod conversions, coming market starts consistently are a through quarter, technology, approximately are with starts. a which of X across majority channel driver, a quarter MDI expand continued and will growth continues U.S. with for Omnipod of driven to the experience, segment, XX%, customer Type us the U.S. in were and by pharmacy AID lives on the record-setting be the MDI even gives XX% the remained utilization that starting that historically primary customer growth notable This to new doubling in Approximately the customers confidence in the customer during customers second large pump of which at a adopting to Type Insulet. of for efficient we drove a pharmacy, our XX%, system. better covered and

which We a positioned expect in well Type are growth we to be to X, segment. we in to is current ahead And our Omnipod X, to accelerate pleased growth extremely Omnipod’s as with this look testament differentiation.

long-term particularly We adoption Type becomes adopted. has CGM potential, market are widely large more driving a successfully also X among as tremendous users, that segment growth

Because Omnipod of that we globe. across uniquely investing awareness for remains is low, are the users. well raise to suited awareness X Type Omnipod learning are We

pilot our advancing the well in are as We U.S., the advertising campaign United direct-to-consumer primarily Europe, Kingdom. in in as program our

helped global starts contributing drive past early DTC our response where customer is stages, to that quarter. And in U.S. DTC encouraging been all factor markets it. and While we’ve has the this believe in remain efforts record tested we a new

and supported living tube-free The is innovation robust our clinical Omnipod Our be life-changing experience expanding we pipeline that diabetes transformative it the participants by unique, is be product We X for to Omnipod from that to diabetes. for our also market. evidence a how cannot will bring technology, clinical shows with superior for community. Insulet wait growth trial Omnipod can and and people know

confidence breakthrough agency’s FDA part and know by smartphone half provided our phone and underway clearance. other progress a grateful We work our close on smartphone to add us and are third in This this the for later app open we space recent is regard, be making to Through continue with related market delighted gives and A the be clearance and clearance. welcomed customers. and a innovation devices be the we FDA is good full is and of guidance so our in things, will smartphone this in timing. that feature, give we product we support to on with control are to towards in novel are complex will Insulet full full Based among a our feedback, estimate control release. a enthusiastically well are ongoing we questions to our is steps expected collaborations limited through working final in the FDA as confidence pioneer Achieving now has quarter the unlikely, their us control. clearance program, fourth clearance clarity interactions quarter. updating the second

committed possible and X as are as We Omnipod getting the to providing to quickly best experience possible. market user

strategies. caregivers with our better life quality through From be market preparing DASH. parity through outcomes. and commercial X, elements testing pharmacy, at core a We Omnipod for work use, be of people experience of market No unparalleled the teams delivers we and pharmacy limited components their the X. all available X through While coverage lives ease and to of we technology will and will clearance, our significantly and pricing the perspective, successfully In it other release. the of and Omnipod functionality believe customer on diabetes Omnipod only improved it are value, U.S., securing will priced the the previously change communicated our for product a access Omnipod of of successful with

We no costs long-term will and period. upfront continue no to provide lock-in

or at X try which able In program, of fuel tubed already our Omnipod adoption. Days XX addition, to pump to Freedom customer, has user free through helped Omnipod whether an time increased MDI any for any will be

Given comparable the U.S. offer the co-pay the given Omnipod majority life same be are this will believe thrilled we approach, Omnipod customers. we to X of and monthly pharmacy $XX, X Omnipod Omnipod value and to expect monthly and quality benefit out-of-pocket the of DASH our have in to Omnipod delivers. costs for our DASH which a a tremendous X MDI, we customers The under low improved is of outcomes

Omnipod DASH what Omnipod We clear, the X pivotal The results limited by as compelling pivotal up people recently data Omnipod setting with and value contracted demonstrated more and diabetes for clinical conferences, at after have release. coverage a non-AID X diabetes for preschool our launch, than deliver successful can shared data. major extension X already commercial including system is to we market had Omnipod us

the data, out. pivotal data stands are we While Omnipod certainly impressive proud of Omnipod all our preschool X

AID parents. results children the many the significant age to significant were compelling data sleep statistically other largest Omnipod age significant strong for results included set experience increase agree for outcomes care. and performance AXc concerned up reduction, accomplishment primary represented The demonstrated study is pediatric in system to Our a their caregivers. age a groups, any The of for overall which and the results an the mirrored preschool no experts as It’s X. on for a down their including quite clinical parents X. up give and XXX% concern phase, systems. most clearly the to of common to and time want the a range shows The in families speaks across severe X’s XX. also into events. very This not these adverse tremendous is value age participants did group improvement challenging moved This extension Omnipod

are to pleased will young are and own. benefit They We We disease caregivers. so and these their verbalize this unable diabetes children often too are vulnerable our feeling see are greatly of Omnipod from X for ease they complicated their on manage the greatly how technology. children these believe to burden to young

speaks phase. was highlight Omnipod the to power reduction further levels Another pivotal in they during X see significantly because a the reduced of our of diabetes were extension to pivotal durable AXC management. reduction already greater the first To transform major

there to do, While including HX X’s continue to map, of indication our X. for are more all our expanding road clinical proud Type in to much will invest we and clinical we of down results, and is Omnipod

timing well, clearance. X Our preschool the internal clinical yet efforts is submission are our contingent FDA Omnipod of advancing upon

indication We now in are planning this XXXX. for expanded

is feasibility and concluded in X-month We advancing. X extension study Type now recently the period are our the Additionally, phase. study

Type X conference. at our of expect We results study an to the share upcoming

the while to remain of is and X Finally, are top believe and upcoming priorities, of our our pipeline best some our robust, Omnipod yet clearance launch we innovations come.

remain in critical data our and such, a science software investing As other development, priority. capabilities

Our development customers. our database underway, iOS work is Libre providing at launch well the integrations, of for international innovations Omnipod aimed X insights and and including

X, and technologies X we people diabetes. believe living lives both Type and Omnipod the developing Beyond are X of simplify improve we that Type will with

working Turning years expand our international expansion, few to global Omnipod key across to and we markets. last awareness access the have spent to

into efforts East DASH the this we our across continue latest for and and Middle year year. expansion where upon earlier have This last been this an builds year. Our launch to Australia, in Europe plan Omnipod Turkey

addressable access drive XX market, footprint. our our million expect will living We diabetes efforts to far with across global insulin-dependent beyond people XX a to the global current expansion million huge estimated international

of market As living diabetes to around the addressable our further we people know additional improve look to world. with are lives ahead, and the help there opportunities expand we

these launch international we We future. the and drive the bring in recent growth expect DASH, markets continue to strong X to Omnipod to fully of full Omnipod our in markets with

we to manufacturing our to and strengthen significantly continue further invest operations. Lastly, global scale

made to to to gearing and track margin terrific enabler We in of are strides expansion operations on critical support pipeline for build the believe U.S. excellence, X and operational we we strong Omnipod future on in initiatives. are DASH, deliver scale expansion results growth which launch on be Omnipod of another to our strong of global for sustainable and our strategic path year progress, our years a geographic a are growing support meet release Omnipod position ahead. of revenue We’ve innovation In up the to our and upcoming demand we and X. upcoming financial closing, the

Wayde. now been I mission over improve will lives have people Our with turn the our has needed. more and innovative to of never diabetes been more call never to the solutions important,

Wayde McMillan

We to are innovation, Shacey. accelerated second quarter guidance and with sustainable, accelerating range, strategic long-term us half through functions second To track solid to position record building the invest of global for global total growth revenue XX% other continue in the revenue generated our in we XX%. imperatives of another the We clinical, year. achieved customer on growth growth. Thanks, and momentum quarter manufacturing in drive finishing supporting by from Omnipod commercial, new our financial starts driven growth, support within our results growth of that

As expected, global revenue QX annuity in pandemic’s impacted effect the on the customer model. starts again new XXXX our nature given of results

low delivered Omnipod Although challenged major continues still in international expect U.S. is of the behind rebates some United million. headwind expectations growth to end we to our States the impact of pharmacy of approximately the pandemic of is of half QX. In Approximately our more at one the the a largest we prior of rebate in revenue to catch-up of the XX%, the impact from to largely linger was QX, our adjustment related $X us. markets, and higher-than-expected from due partners which

$X approximately a tough $X channel million to the also year. comparison reminder, As build million had in QX prior of a with

pharmacy continued we the both volume starts, with and build with as we and mix quarter, customer base second Omnipod adoption increased growth through customer the record DASH drivers customers drive realized X These DASH new channel. X the finished international Type our to During we pharmacy to benefit Type volume U.S. starts of ongoing of expectations. which U.S. to grew QX grew over continue our we drove and upward revenue XX% U.S. XX%, trend QX, ahead as XX% Omnipod customer In channel in new total of almost Omnipod volume. our our slightly

quarter execute team’s Our challenges. successfully growth DASH the as COVID-XX as customer through driven to by our Omnipod markets, our base was our success in the throughout in with well ability continued expanding

our utilization Drug finishing slightly quarter, and stable revenue ahead during expectations. remained attrition global declined XX% QX. of Our second the delivery during

and operations as a As in a a result elevated are XXX point constant basis XXX year year pandemic prior the Gross basis increase was were margin the basis and expectations EBITDA investments, by adjusted by basis. increase This expected. quarter, clinical mix as as be U.S. down pipelines, a Omnipod the to and which currency was highest our offset invest initiatives and highly U.S. margin expansion pharmacy chain our improved basis global our third increasing was of innovation upcoming other marks with our in including COVID-related expenses the were and line we and channel. costs supply international is robust of a XX.X%, reminder, up the points, of now including XX%, reported points. order manufacturing, volumes on plans. point benefits product. as higher gross direct-to-consumer gross line expansion to XXX in with Overall, XX advertising efficiencies, expected producing in date. margin automated to was second in driven These Operating sellable and our continue this in our benefit of XX.X% mix we the U.S. margin to representing launch the Operating our continues manufacturing or normalizing were volumes continued commercial X partially costs lower expectations and line, expansion our ramp margin

invest to business throughout fuel line was continue long-term Our to growth trajectory. our our operating our we as in with expectations income global

with liquidity, no the cash in cash and $XXX continue runway position and ended in strong invest short-term and to business. Turning investments. We we to in our million to a maturities further near-term with remain quarter

from financing. executing in strengthen We structure, our to of a $XX successfully million including XX% taken $XXX loss the that Loan of resulted EBITDA. used due repurchase steps also extinguishment which proceeds Term excluded capital on convertible have a XXXX, to our number notes B We million a adjusted is

since issuance were and outstanding. of original notes the X% Additional approximately converted now remains

million will be to approximately Following these $XX we reduced million. basis, interest approximately and million expense transactions, expense on to interest $XX an our will non-cash be cash $XX net annual significantly expect

of the revenue XX% turning remainder to total year, outlook growth are Now Omnipod to revenue our XX%, to year guidance our maintaining for XX%. we XX% full of the of including

XX% continue to a revenue year XX%. U.S. of Omnipod to full expect We growth range

growth benefit primarily and increased awareness, the the our access be pharmacy channel. our differentiated and expanding expect We to volume, in pay-as-you-go model, DASH by Omnipod driven mix

In than previously anticipated addition, we are we adjustment. QX expect further incremental rebate X penetration adoption offsetting revenue both X the and and Type in and markets. X customer Omnipod Partially the tailwinds Type less had these

For of international continue launch end Despite in of expect COVID is grow see growth. of The has growth runway its our lingering continue several impact to clear year. XXXX, our near Omnipod, for our we of XX% of adoption across markets growth. to penetration new XX%. successfully we the adoption pathways range large, full a during the last to following DASH strong driven first year expand to additional Omnipod Omnipod team and rates customer half revenue the across XXXX future markets market and international

comp to $X we As launch a a initial of from inventory the prior our million reminder, we due in $X million pandemic-related year as had Omnipod tough well to of experienced the DASH. as

range drug are expectations maintaining to in delivery X% increase. decrease we Lastly, revenue a of for a XX% our

core in ongoing full operations, efficiencies U.S. of create scale shift well the changed we now benefits our have gross as margin, volume drivers of manufacturing margin XX% be pharmacy channel. expansion of to expect year our and margin the build gross as XX%. the to Turning gross throughout we range not The as global to into

lower expect we from COVID-related benefit costs. addition, to In

marketing in investments our consumer-focused We critical year. operating line international as to expansion innovation, view will revenue our with rise expect our and expenses in largely continue growth and long-term sales the teams efforts We to this profile. growth

range. low margin operating full reaffirming digits are year double the in We

the by growth not quarter be revenue will expected year margin our primarily as we improvements to throughout the On improvements the expansion driven that that as Our recur our second onetime well will strong due operating of half top our in and margin costs basis, expectation line accelerated a year. occurred this gross sequential year last of this margin growth. operating expect fourth

We to as as investments capital to increase this strategic throughout global with expect our manufacturing year continue operations, our expenditures the initiatives. well

XX%. our XX% XXXX of expect XX%. to guidance, total growth Turning revenue we third XX% growth revenue to to total This includes quarter Omnipod company of

XX% expect We of revenue U.S. growth QX Omnipod XX%. to

in As a year. the distributor from step-up stocking The our last year, quarters the to quarters, and is related ramp degree, through volume annualizing impact the a the the accumulating channel destocking customer the pharmacy primarily reminder, prior QX growth significant from due from to most also in growth benefit COVID-XX net estimated record-setting our from channel of and, XXXX benefits channel. impactful sequential impact volume rate new destocking start lesser of mix

We of to growth international revenue expect XX%. QX Omnipod X%

is growth rate channel in DASH. distributor our international of We in existed the international to to million continue many of be QX stocking full markets. first we the of of X release of the offset of the second our X partially reminder, million half trailing year a last the as impacted this estimated to expect pandemic-related Also, that quarter Omnipod ahead half headwinds by the and by growth experienced XXXX third year, market in

sustained prior year compared growth We normalization from volumes and to the our while strong the momentum decline the to revenue in are business expect strategic on margin of levels advancing revenue have In XX% imperatives. due conclusion, delivery year drug another we resulting as and throughout XX% order pandemic. expansion to of to deliver track to elevated the

innovation sales position the efficiencies. awareness leading and and provides Our is force, manufacturing international and initiatives, to sound us expansion global our in pipeline, flexibility access financial invest

designed over value globe. the of the that, our call efforts operator the these are to lives we long-term improve diabetes the the drive of All significant will with people over strengthen questions. for ability and shareholder to across With turn to

Operator

Travis question from Barclays. Please Thank the comes Steed line from of Instructions] first go you, sir. ahead. [Operator Our

Travis Steed

Omnipod of Hi, the sure and color moving by are get the did have you the I missed And on delay. X I understand what the just happened Pod make parts exactly thanks but you gives prepared so going the want all part QX? to to remarks, I for what approval more apologies, confidence questions. there, to that

Shacey Petrovic

Sure, I the Travis. Yes, appreciate question.

on be to for had may We had there agencies’ surprises, it our think track put a us no on helpful which and May. back submission, where received take were step in our we anticipated to I were timeline. the feedback

and agency. that are very of the be collaboration the allows fortunate program, We us frequent a part to breakthrough with devices

So that our FDA’s detail for and in we to get us on the feedback clarity phone feature prompted and app us really valuable was response. believe helpful more control Their to will a extreme opportunity took full the with the discuss mobile update and it customer improve we experience.

since market And happened assessment May. work and and towards then what’s then, normal work and FDA’s that we us including basically not the testing. of underway, course, puts of some And our given is buffer that because late all review of and load, all that times the limited is work So in clearance our validation QX COVID verification well believe, final a the release. are QX,

are. making of a we So clearance. really the still, preparing of standing where just in while and the work release time good the that kind meantime, I market doing get are limited I think use final would we to great not are have for that emphasize we teams that’s we

Operator

show next Thank Biegelsen our line question go Please you. Wells from comes of Larry from Fargo. I the ahead.

Larry Biegelsen

get to that to FDA? taking delays Thanks given to And my submit one for what QX question. the on Good guess and if to afternoon. what X, I will final what’s to there, for when Shacey? question. going I I use the guess do Thanks you clearance? you gives are just the And Omnipod buffer the plan is you confidence the ask am that I late feature question that taking incorporating

Shacey Petrovic

to Larry. control. related Thanks, feature The Yes. smartphone is Sure. full

with app study. across of AID system range know clinical to our way So pivotal the interacts it’s algorithm, system. broadest delivered nothing results the age we our that any do with core outstanding the the which has or It

believe of deliver confidence with feedback that nothing we gives ultimately, functionality, helpful is was What is release in when and system the will think helpful think, our buffer. all limited is the provide but learned plus experience. customer that the of work quite And think impact but review because We’ve something don’t while been time the market a I us under we it’s we in that this the better QX to has will agency. what a have I plus say it factored well. time, lot us. exactly review pandemic some we’ve will underway interactions about So amount all we’ve for buffer, I for been underway as

what So, we factored longer than taking, do back that forth been understand how that’s much timelines, that’s the QX. and points to us been in long traditional and has how we’ve

I like confidence. limited a think half, confident give and enormous amount of this in have the And remain that here that until stages we those but market cleared us QX, time, final hurdles. second in and So we of interactions really release said, we it’s we Up believe an really end are clearance.

Operator

Thank question next the go you. from show Marcus Robbie Please ahead. JPMorgan. comes from line I of our

Robbie Marcus

One obviously I ask for they And you in it just second pharmacy impacting put Great. the And great Thanks. will further then little the of the any going this if field. starting from are was it’s I it hear back you back Two Do – Is better do expect me. into Omnipod how the payer impacts they about X, are Thanks. – did the results it and you about just you’re it that? But hear sure this waiting from out in. forward? and Omnipod at the as news, on a was back? thinking rebating we the in on when to people Was rebate more be are holding are think you it for am over-earn that one-time? what think how would now exactly you U.S., all? worked. How could go rebate, field hoping seeing both that what I them you upfront. detail on

Wayde McMillan

Sure, right.

little it It glad due I partners. want, you it. one question, rebate Shacey, an information start share you it of around is our If pharmacy can largest one, up, rebate because a updated and on brought us to that more color gives Robbie, from opportunity an to the bit

expectations mentioned catch-up, changed rebate to we as as prior well. remarks, partially in and So result to it’s QX year-to-date and prepared the that that related a our

arrears So a have pharmacy. quarters ramp their we our as wide in strategy percentage have our the our and pharmacy we correct of in rebate to submissions, and several range execute and partners business rebate programs

So we the variability anticipate in rebates.

was one us, new of both partners. really expected. for growing this a It’s pain much it’s larger It’s However, than for us. for and new our pharmacy

going as set of forward. this we’ll us, type for of they process majority we think this Once rebates over in down up a agreements and So time. variability the our our don’t get business get settle I will pharmacy and more see established,

rebate higher for pharmacy. doesn’t change expected, strategy the ends up in much is It and a our customers. than the our us better for differentiation quarter this Although net it significant

rebates see it guidance, impact we end variability. will low do larger we is forward. channel to that could percentage given both metrics becomes rebate a and the as end. results And the be some relation there, the difference revenue, pharmacy portion one So the of the a going high our of – metric that In factor our into

Shacey Petrovic

say a physicians pillar a Yes, it’s we new strategic efficient I better I patient one your channel customer emphasize Robbie, for us. think because but business it’s Wayde. just a more Omnipod the The for behind is ready And as and numbers, for to reason, of hearing numbers, Insulet, it’s also of obviously, really had Wayde we mentioned start and X. And that what Thanks, the and thing think But the lost important in the then field. record are question, on the it important as experience, gets quarter. behind with scale model. sometimes that’s is pharmacy for to launch the get a all, I Great. we important we would

be not growing and people in X. think e-mails certainly that’s personally based waiting. quarter. get evident So past that that this numbers of you’re are from as company right starts we there And The on is I important awareness daily customer holding said, new Omnipod about would anxiously off? are It that in our customers consumer

believe awareness So are is customer starts of new but based don’t on there off coming. customers growing I the technology that’s holding the numbers,

Operator

next Danielle show I from comes SVB you. of Thank from Please go question line our Leerink. ahead. the Antalffy

Danielle Antalffy

afternoon I Shacey, I taking is XX% X at approval the much with looking or this coming Thanks XXXX. in growth the now for And guess or question. if everyone. know year, was good Wayde Hi, this so later like maybe you. for pre-today consensus But of for don’t Omnipod both

X in if Omnipod how via So a market at midpoint all, that you’re accelerating be? I achievable be limited about of curious change and X. you how how Omnipod again, slight at the numbers looking pre-today, range. for say what might impact I’d mean the the so timeline can if just a the much. talking that growth release about acceleration for you’re outlook consensus still the the for might XXXX, Thanks

Shacey Petrovic

with Omnipod then Yes. some color to XXXX he wants Maybe Thanks, can give I’ll kick any X. Danielle. off, Wayde and give us regarding comments on

for think Omnipod the I waiting we market that X. ultimately, know is

important we to make So to whatever market limited release. we’re can limited going as our It’s possible. a efficient release as to do do market

pumps, or about or have different multiple injections or use different what’s requirements. think are coming know pathways, journey to They Omnipod people DASH that happen have to they X. with on a customer X, we today Omnipod you tubed will different each all and we Omnipod who If classic going daily are going to

pharmacy already For and low know costs. example, all customers DASH our of benefits the out-of-pocket

the users have MDI training the of have then comfortable each with We’re patient pump those and of onboarding different users to segments benefits pharmacy different potentially and going or two to get needs.

that the customer And are everything is for those launch. governor that reasons so one testing And a make progress access. got great that some we experiences types today that’s the access. to then the And making establishing gave the why we’re team we’ve of of color sure the great is other in position

And a one. But sure, we in quarter now, hopefully, doing a efficient than we today are going a be we everything better – as ago. can LMR for were today, to not are want even we’re well, an in do And we hopefully, stronger make So do that position. we as quarter we from an to position possible. to

in hopefully So XXXX really efficient the and as possible. I strong keep position we’re as head into to going LMR think a

Wayde McMillan

And Yes. some picking part appreciate Danielle, And up can certainly how there, XXXX can we aren’t include provide ‘XX But about we’re guiding the for for Omnipod ramp guidance a on at to XXXX. color question we point time. XXXX strong U.S. the is this on And in going the will us. the in to just of question. yet. X the thinking of guidance be we year

her remarks, you’re QX, as Shacey that with the in that expect extend into market LMR starting asking the as full However, likely at XXXX said some the and we end of later would release of prepared in here, with portion coming XXXX. most now LMR about that sometime will

market point, full a but full get is likely a – it strong for going so And us. a year XXXX this be won’t at release year very to in we

point. specifically of this the not pandemic But in got always will consideration. numbers And persistence or so the annuity at on a to other of of ranges our be here And for and model think guidance comment ways couple given A go a about, to is things of here ‘XX. to headwind we’re rest pandemic XXXX, somewhat it throughout the into the we’ve XXXX. us a going

wave be do will adoption of the that through coming going QX Type so as variant XXXX. in guidance XXXX. as our DASH progress it yet into carry We of have challenges then But momentum tailwinds CGM, X rest drivers what penetration, usual, I the of out some us. that call. in think the And give warnings X that don’t other here We in will well. accelerating by we see the we’re how and Further half, how and But things growth customer XXXX. let’s we’re see aided countries into second really to riding that and the free clear Type the are and are and and Delta will some impact being

the We’re pay-as-you-go to direct-to-consumer continuing expand with our our pharmacy model, program. in

into couple that’s XXXX we are headwinds of guidance get the some quite lot our a of QX a will you, monitoring momentum in a few that we for So, on tailwinds, business, and color call. the

Operator

from of question Jeff comes you. Baird. Johnson the show go line from our Thank Please I ahead. next

Jeff Johnson

afternoon Thank guys. you, good

Let LMR a getting you’re your one Shacey, and full in there there I there. it you’ve Wayde, coverage and Is I – but fair And ask and kind maybe quarter question good that limited quarter coming moving we to about When market ‘XX progress maybe point, market already a established? either guidance, place, it commercial guess, it – in like into think think, Shacey, that X-month was know me one midyear giving was of respect of you’re given that that Danielle’s it then should not half? making that, lot as by release? be just could it Wayde or commercial on X Think follow-up release. Thanks. sounds then about like LMR way. schedule it of slightly so, some different to second feels the shortening a thought or coverage Omnipod I be was But cut

Shacey Petrovic

Yes. Thanks, Jeff.

are in to release as efficient limited drive as to that everything market We we can possible. going do a

is to something limited in in I testing that of market designed things releases and keep all to uncover just preparation. contemplated mind think launch weren’t the are

that’s So I caution. think the

we position. course, Of are a in stronger

We’re securing coverage.

into release. I market trying this of we limited to market up if address a shorten That’s something for release. are doing sets to going success all But that. the think we in whole everybody I the purpose limited bump us saying, by caution of and

potential certainly and running teams and of with we’re doing, doing which are ameliorating work, are of certainly that is main the the the we into governors. the all great access, establishing one of I work think something

providing But are limited the best release, possible so And our sure market we’re make course, I going signs. from great experience. and to going take to the those don’t that – of learnings customer we’re we’re

Operator

next ahead. Sandler. go O’Brien Please Piper comes question from from Matthew the of line show I our

Matthew O’Brien

Good afternoon. Thanks Shacey, But for taking about patients that there if patient some more dynamics I’m much so And business. if the you your in of question. the the I additions it’s that are the you core know talk higher pediatrics. that bit growth the everybody was Can is new a focused about on to it’s here. the point, curious X, slippage little new Type record Xs, driving saw.

Just next on and some how those so might, you those then Thank talk dynamics get X about year. market of you. the may once be can augmented more

Shacey Petrovic

for happening now. growth? right Yes, what’s think our to well, core business it’s question. driving would I to I – exciting dynamics. see What’s point with Matt, two really thanks the the Actually, three

DTC. is first The

a X, Type – So And and raising injection one think this investment that drivers users starts. we patient quite for our multiple daily awareness broadly we’re record in was Type among bit U.S. working that’s making is and in the coming X. new by across definitely of primarily then the also

be Type so to. would X second And would dynamic the point I that

We and Type are simplicity user rarified else market the Nobody that unlocking this product having in cost well we’re And have is in in we pretty uniquely X the that having a its position profile. success it’s is a to here. opportunity. its suited because

accessible pay-as-you-go. aware underlying that’s more is affordable to third that And and things. dynamics, it why these reason to Omnipod the helping more it. these launch the And are increasingly be so we like and becoming X, when people the to we certainly And make is dynamics our technology of additive the that’s piece, because pharmacy these will

market. advantage And our intend what X intend Type maintain will a advantage to our we in fully think going in pay-as-you-go game-changing We our we model. technology deliver – and to then to be the we’re the are Omnipod We to in fully maintain pharmacy X.

be of right will we’ve patients. to underlying of all got gearing the we’re And excited incredibly – that’s deliver now launch is aspect up company new so because not – gearing more record-setting And helping to it just could what for and course, this about Omnipod the team momentum X an excited being every that’s up patient starts. bring

it’s So strong U.S. already think to I is exciting particularly in business, the what really a an additive our momentum in technology

Operator

you. line show ahead. next Kaczor Thank from the from of William comes Margaret I Please Blair. our question go

Margaret Kaczor

It the this in adoption taking the Hi, like and quarter. wanted patient it focus and everyone. for starts kind well. as users active I question. pharmacy Thanks increase on seem that up, perhaps of to new did does for for certainly pop channel in

be and something timing of that there little predetermined it Omnipod bit just launch a to we a uptake? you I is from was different Thanks. that base more So to guys or we guess, drive as doing year active now, Is should on X? see look DTC? And were that it where the going

Shacey Petrovic

Yes. Great question, Margaret.

continue the few access up And and increase our pharmacy. then move there increased So happening. as the opportunity to notably. One, have we into to is in we a access, that people tick base things more

piece one that’s So it. of

each directly DTC quarters vast our where The is directly record-setting at think demand. to that cumulative pharmacy. mentioned definitely pharmacy customers second starts, on or XX% now, new majority of I quarters, of DASH, into the think going – on XX% the the is in And three driving if you in got quarter, Wayde where and those about between we’ve customer so of

into to trend drive pharmacy. more the is more that people just helping and So

majority big over to we expect see terms business and majority in our think available will existing a driver years. do where in users of pharmacy. the know as the there coming the also of does go, the growing – fully only in X Omnipod I have the among We that our pharmacy is demand this vast market. Omnipod be there. We X or among

And continue business pharmacy. that into the point Type I is so move through us to would that Medicare to of X, the to pharmacy. all will And help also accelerate our

does X the Omnipod providing growing tomorrow. it’s and pharmacy, today, even as Type remarkable at grows, pharmacy more multiple in and for Omnipod injection, be daily remarkable to a that’s DASH cost really thing. is as that it’s great X same by out-of-pocket the So going for What

patients. So, just for effective really great cost our therapy

Operator

our from of comes show ahead. Please go Raymond the Jayson I you. James. next line question Thank from Bedford

Jayson Bedford

the launch in good make on you kind hopefully, and Omnipod mentioned on if going isn’t this repetitive. you efforts limited, this afternoon. less your contracting access, But you frame just been contracting me, with Excuse of X. so and that question will? are with Any does you progressing way where can I’ve you’re out,

Shacey Petrovic

Yes, question. Jayson, great

with more rather today details, we preceding with established, than giving access, lives of conceptually DASH. access covered launch are we Omnipod Omnipod kind So with than have we where following – just more launch did we X

puts launch. quarter, us, closer get a to trajectory that Every as establish for access I and really more Omnipod really in a we So think, X. strong we position nice

one get what think I to and closer So to use great as that we And we making is hope, release, certainly a time. for are as certainly there. to launch, but successful, your primary note, are governors two you market limited is point, making very teams us there still, knew a that this not And progress team standing the access. up market release. of great sets efficient the is we we’re limited Because

really The of other to get we we is customer of sort be throes say that’s can’t experience. into And one where how quick until the it. going the that’s

of look all onboarding that’s team patients the testing the thing think different I nice testing move But all doing doing and really you that release the limited the need the think, release, of access. processes, testing is stuff. the a given governor with we’re from market will really type market full be, as the test to I training how well benefits into to of primary But job going we pathways, that investigation, effectively. that live through process

Operator

Please I you. Rose next our line ahead. Kyle comes from go Canaccord. the of Thank show from question

Kyle Rose

question. bit second the Great. time maybe Thank ask calls to I these this making talked investments you mean, wanted on third of software. a you’re just is picture a for in question. or bigger the I taking about Shacey, in you

touch. to maybe and maybe products us widgets understand physician providing? about, like the the accustomed might experience the generation more that help technology focused of tech with how tangible not pumps you on traditionally, O-X, more how maybe products Maybe focused. of you things, to just think and patient think we’ve I insulin more next med the value in can software become that and be are going necessarily but change that being the you’re And

Shacey Petrovic

question. thank you the for Kyle, Yes,

we have talk a access ourselves they earlier course, controllers. how being on position is data as to system. us with will real-time of that call that phone glucose which it that helps our the a eating. the understand continuous previous are their And few how offering we’re X we delivered, means companies data the great we patient into a to to mentioned Insulet think in cards have Very it’s us then, us being of Omnipod We stream about insulin of much just understand see coming had have with how suspended, putting X. that control, interacting will be I helps full relates SIM will is opportunity that off data. Omnipod volume when user when doing, Helps they understand are of

can And potential so provides to with analytics. well in be potentially that incredible that generate payers us our valuable population to insights to to as customers, and clinicians their

believe it’s wearable we data mechanisms. through can us that see we variety real-time better that’s help outcomes a just because technology help people positioned, ourselves so a providing well of achieve really And essentially

for we’re including I believe about well more to to we payers, that customers, value we Omnipod and talk X hear our how very clinicians that do us here. in see and market, we our you’ll our our get positioned So that think but our consumers, role provide as

Operator

I Citi. question of Joanne show comes Thank line you. ahead. our Wuensch from next Please from go the

Joanne Wuensch

the taking Good for thank afternoon question. you and

it is any just is, comes a to X thing back, Does things is mean I accelerate need or there of address the Does that think have is X tonight of in it, out launch? your And there it maybe months? pushed everything limited that one way is positive patterns to Abbott’s the the call delay? label that of Libre? your you this or I’m hearing Type questions product shorter a with

Shacey Petrovic

to feedback I Yes, really this better. a be positive us limited given Joanne, of enable time even also is ultimately that that thing we’ve will that market a shorter is deliver as I of – has this and believe that that had the establish coverage. will release result FDA that think helpful comes the think out to us valuable, we product the But

to shorter? to understanding if there that value really How rely the good. customer But us learnings the market got have is been able That and incorporated need is more experience. help adjusted those will experience we’ve Both time testing efficient continue during to a us customer deliver that just be things opportunity or much establish the that limited on So to test this the we’ve to. to release. of coverage should and

Operator

ahead. Jefferies. Thank the show from question of comes Petrone I Please you. from Anthony line our next go

Anthony Petrone

in some with is doing hope A days. on Omnipod I couple bullish the on had the they behind on language just question collaboration past earnings call X everyone well. their of scenes Thanks. Dexcom,

behind on opinion the follow-up sort the ahead later So it coming insulin space, evolving collaboration and And delivery that is would we how maybe then of wondering consider question on question. the X be next of term, to That you either launch you level to when X what scenes the view on this just of, imminently? now first going a longer year. market be just automated years offerings, have or see multiple market Thanks. would

Shacey Petrovic

been offering. collaboration incredibly the outstanding been partner, obviously, in been our they technology. that helping combination and drive excited an could have has and us for be incredible They we AID strong. We to adoption, not to have across Dexcom believe they it are helped done more Anthony. really has consumers. of and number a And so they market has fronts see have provided they remarkable Thanks, and value that the an what

game that market. in terms the our and outcomes, to market will changer it game is in position. so Omnipod changer game X, changer in of with in going combined patient of the experience It be And patient Omnipod a and and think be a a will terms we be

GX strong collaborators, course, and integration. future and of strong on we’re working So then, partners today,

really so as And be of that well. exciting pipeline would our a part

will occurring what’s that very trend happening In AID AID what’s Type insulin there. I exciting CGM part gives among market, think the And X great market be of And in delivery. among Type pump Xs. with out will adoption see the big now confidence to a the automated double. terms We of of users, it’s that see terms us

to us – system. that I and that the non-AID think product market or the thing our to so deliver going believe Of we gives the with to market. we’re best we excitement And best been have is course, competing effectively

are dramatic though seen choosing there even that in And so, people no we’ve and such is despite fact uptake integration, CGM CGM. the Omnipod

we’re power which with because of that if alternative Omnipod now automated we’ve think no another choose we an will that of longer device, we really integration real the because people have system factor going and delivery see the insulin So choose form people to pod X, factor they form but to CGM the reason many a integration. Dexcom prefer got know –

really to frankly point really Type ground field playing even I and other X. then And just leapfrog the is would thing so to the we’re there excited And there. the

say lose sometimes today, more maturity All here, of among still competitive X. there would Type They of if in but field, the at are I no patient Type these I you trends in look And north is the one talk are large win. population, more of mature to us needs – are using about field, that for this really X where pump somewhere even therapy. patients to third

just for better X diabetes. a for with Type of us and all to outcomes there opportunity burgeoning impact technology, living So provide is Type patient among trends The better X. people great care same are

so integrated we’re our and about that Type going position grow are devices both expect Omnipod too and over really among to the there, X users and excited certainly X years. And we coming CGM

Operator

from from of Misra Please our line comes I question go ahead. the next you. Thank Berenberg. Ravi show

Ravi Misra

evening. Hi, thanks for taking Good the question.

picture. of more bit that big last So on jumping just kind maybe question, a little

your a But getting it you right of You things XX% pumps telemedicine just there put that’s something that that and pump market. do is, XX% insulin to existence but said on significant control? the in is to of kind terms new that curious, in philosophically, maybe do curious from if not technologies on statement. Thanks. what of and majority of you access of work now, of needs I earlier delivery today, think is just lot kind think doubling through potential that just us support of what still kind here in with could going I’m can

Shacey Petrovic

we so adopted how we them. technology simple I talk be quite you we that can the those. can easily few think about technology would you it of a both of can When Ravi, those, say of simple How by just both access, highlighted it Omnipod for many is make we’ve enthusiastically people and make in I we to simpler. can game access. and today, are Because to the and make too hurdles new simple get to still continuing still eliminate. pharmacy how to and masses, there to work today, But it technologies, is that’s on with pay-as-you-go these the the committed has changed something made and for

simplicity DTC. So last would technology, awareness. point and access. And is really we’re the I and to would simplicity point I seeing it with And thing to

the around somewhere of investing consumers’ awareness We’re because before at the in everybody the saw awareness, even patients’ was impact their awareness. patients that awareness of invested we’re awareness, and unaided what we helping we in options, a X big to technology. XX%. in probably But Type And increasing we’re making DTC market was end a day

the a X So even manufacturer XX% Type pump name a person of with time. only could

understand help And more them. to here to gain need So a we to to simple just that options awareness to and to use. people available there them and and the opportunity treatment access is massive make then cost-effective are

Operator

Oppenheimer. Lichtman I ahead. our go show Please from comes from the you. next Steve Thank line question of

Steve Lichtman

I relative over internationally talk focused you on Shacey, What next, to Is should X you we could for the are wondering be you. guys Thank the XX was months? international. talk whether potential drivers has countries incremental about recently if Omnipod can say, biggest the where of particular and or terms launched X countries DASH outside about – new of you timing Thanks. to of it’s U.S.? in it anything

Shacey Petrovic

time. DASH way Steve. but contribute additions, room doing And market be works. that added and of across business international will the new which of to continued expansion accumulate will Thanks, users. our any last to know in drivers, there, we’ve It’s internationally about or there. But well adoption DASH, think that really internationally, a the Yes. for we time and When so markets year international handful us continue our particularly Omnipod markets, model is grow the the just we now new addition, to new over so, takes market drivers

driver. in the as that growth new growth long-term and also We, time. international a course, driver, drive view we X are Omnipod markets continue view will will next international markets, of we So to excited we to our expanding growth as to invest which bring into over really

We And work, Omnipod could Libre that Omnipod about, we the in to and international. all is I program yet. timelines a things we’re every can once aren’t on want really on market and update give We going X then to we integration, everybody iOS that asking get to not timeline integration, our U.S., be But to mentioned GX the as to to which that first get market of X just in as going aim we underway. certainly, more to quickly we is follow excited U.S., do. will

Operator

Petrovic Please turn I’m Shacey like back conference Thank would no over at showing remarks. I for the now ahead. this closing go time. questions to to you. further

Shacey Petrovic

joining for everyone, you, Thank Great. us today.

to As outlook. see, we and our the and in our throughout strategy momentum we great drive you continue business can real have forward, confidence

will we new great just much. Omnipod those important Thanks Insulet for more year what X for evidence are launch The living so the we clinical Insulet. X, we halfway technology with those Type and value and for because another Have through are worldwide. X be diabetes shared be successful mark we offers Type chapter speaks more evening. diabetes. importantly, not confident to and, it of the expect year could excited will a We for the to living an tremendous with our And

Operator

day. have this for wonderful participating gentlemen, Thank today’s you Ladies concludes and a and conference.

disconnect. all may You

Insulet (PODD) 6 Aug 212021 Q2 Earnings call transcript